Chronic Rhinosinusitis (CRS) is incredibly common and expensive.¹ Nasal steroid sprays are prescribed as standard of care, but are ineffective, and “appropriate medical therapy” (sprays and pills) fails in 50% of patients. This leaves patients with options of continuing to take multiple courses of oral medications with serious side effects, having expensive, invasive procedures, or suffering with insufficient treatments.

The innovative Nasus drug delivery platform is designed for patients to treat themselves at home, earlier in the disease.